JOP20170029B1 - C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1 - Google Patents

C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1

Info

Publication number
JOP20170029B1
JOP20170029B1 JOP/2017/0029A JOP20170029A JOP20170029B1 JO P20170029 B1 JOP20170029 B1 JO P20170029B1 JO P20170029 A JOP20170029 A JO P20170029A JO P20170029 B1 JOP20170029 B1 JO P20170029B1
Authority
JO
Jordan
Prior art keywords
hiv
inhibitors
compounds
modified triterpenoids
triterpenoids
Prior art date
Application number
JOP/2017/0029A
Other languages
Arabic (ar)
English (en)
Inventor
Chen Jie
Chen Yan
B Dicker Ira
A Hartz Richard
A Meanwell Nicholas
Regueiro-Ren Alicia
Sit Sing-Yuen
Sin Ny
Swidorski Jacob
Lee Venables Brian
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Application granted granted Critical
Publication of JOP20170029B1 publication Critical patent/JOP20170029B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/52Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOP/2017/0029A 2016-02-04 2017-02-02 C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1 JOP20170029B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04

Publications (1)

Publication Number Publication Date
JOP20170029B1 true JOP20170029B1 (ar) 2021-08-17

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0029A JOP20170029B1 (ar) 2016-02-04 2017-02-02 C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1

Country Status (39)

Country Link
US (4) US10421774B2 (https=)
EP (2) EP3411381B1 (https=)
JP (1) JP6735837B2 (https=)
KR (1) KR102795662B1 (https=)
CN (1) CN109153700B (https=)
AR (1) AR107512A1 (https=)
AU (1) AU2017215529B2 (https=)
BR (1) BR112018015629B1 (https=)
CA (1) CA3013417C (https=)
CL (1) CL2018002084A1 (https=)
CO (1) CO2018008157A2 (https=)
CR (1) CR20180387A (https=)
CY (1) CY1124353T1 (https=)
DK (1) DK3411381T3 (https=)
DO (1) DOP2018000174A (https=)
EA (1) EA036211B1 (https=)
ES (2) ES2862325T3 (https=)
HR (1) HRP20210502T1 (https=)
HU (1) HUE054337T2 (https=)
IL (1) IL260741B (https=)
JO (1) JOP20170029B1 (https=)
LT (1) LT3411381T (https=)
MA (2) MA43960B1 (https=)
MD (1) MD3411381T2 (https=)
MX (1) MX375118B (https=)
MY (1) MY199668A (https=)
PE (1) PE20181355A1 (https=)
PL (1) PL3411381T3 (https=)
PT (1) PT3411381T (https=)
RS (1) RS61746B1 (https=)
RU (1) RU2716502C2 (https=)
SG (1) SG11201806388XA (https=)
SI (1) SI3411381T1 (https=)
SM (1) SMT202100210T1 (https=)
TW (1) TWI719126B (https=)
UA (1) UA123867C2 (https=)
UY (1) UY37109A (https=)
WO (1) WO2017134596A1 (https=)
ZA (1) ZA201805044B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025037232A1 (en) 2023-08-11 2025-02-20 ViiV Healthcare UK (No.4) Limited Tosylate salt form of a maturation inhibitor for treatment of hiv
CN121909019A (zh) 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
CN103038245B (zh) 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
PL2670764T3 (pl) 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
EP2791102B1 (en) * 2011-12-14 2016-05-18 Glaxosmithkline LLC Propenoate derivatives of betulin
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
SG11201506445PA (en) 2013-02-25 2015-09-29 Bristol Myers Squibb Co C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
SI3129392T1 (sl) * 2014-04-11 2020-11-30 VIIV Healthcare UK(No.4) Limited Triterpenoidi z inhibitorno aktivnostjo maturacije HIV-a, substituirani na položaju 3 z nearomatskim obročem, ki nosi haloalkilni substituent
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
LT3984994T (lt) 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti

Also Published As

Publication number Publication date
KR20180105229A (ko) 2018-09-27
CY1124353T1 (el) 2022-07-22
MA43960B1 (fr) 2021-02-26
EP3411381A1 (en) 2018-12-12
RU2018130181A3 (https=) 2020-03-05
AU2017215529A8 (en) 2018-08-30
CR20180387A (es) 2018-09-20
MY199668A (en) 2023-11-15
EP3831839B1 (en) 2023-07-26
RU2018130181A (ru) 2020-03-05
ES2957767T3 (es) 2024-01-25
CN109153700B (zh) 2021-03-09
HUE054337T2 (hu) 2021-08-30
EA036211B1 (ru) 2020-10-14
DK3411381T3 (da) 2021-04-06
WO2017134596A1 (en) 2017-08-10
JP6735837B2 (ja) 2020-08-05
RS61746B1 (sr) 2021-05-31
MA43960A (fr) 2018-12-12
US11084845B2 (en) 2021-08-10
DOP2018000174A (es) 2018-10-31
SG11201806388XA (en) 2018-08-30
ES2862325T3 (es) 2021-10-07
MX375118B (es) 2025-03-06
US20230295220A1 (en) 2023-09-21
CN109153700A (zh) 2019-01-04
KR102795662B1 (ko) 2025-04-14
MX2018009514A (es) 2018-09-05
SMT202100210T1 (it) 2021-05-07
PT3411381T (pt) 2021-03-18
BR112018015629A2 (pt) 2018-12-26
CO2018008157A2 (es) 2018-08-21
HK1256866A1 (en) 2019-10-04
MD3411381T2 (ro) 2021-07-31
CA3013417C (en) 2024-01-02
AR107512A1 (es) 2018-05-09
TWI719126B (zh) 2021-02-21
EP3411381B1 (en) 2021-01-20
JP2019504104A (ja) 2019-02-14
BR112018015629B1 (pt) 2023-10-24
UY37109A (es) 2017-09-29
AU2017215529A1 (en) 2018-08-23
NZ744545A (en) 2025-03-28
HRP20210502T1 (hr) 2021-05-14
MA53358A (fr) 2021-07-21
UA123867C2 (uk) 2021-06-16
EP3831839A2 (en) 2021-06-09
PE20181355A1 (es) 2018-08-22
US20210323997A1 (en) 2021-10-21
US20190359647A1 (en) 2019-11-28
US10421774B2 (en) 2019-09-24
RU2716502C2 (ru) 2020-03-12
ZA201805044B (en) 2020-08-26
CA3013417A1 (en) 2017-08-10
CL2018002084A1 (es) 2018-09-21
PL3411381T3 (pl) 2021-09-13
US20190031709A1 (en) 2019-01-31
IL260741B (en) 2020-04-30
EP3831839A3 (en) 2021-07-21
AU2017215529B2 (en) 2019-01-31
TW201739757A (zh) 2017-11-16
SI3411381T1 (sl) 2021-04-30
LT3411381T (lt) 2021-04-26
EA201891649A1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201270800A1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201590862A1 (ru) Фармацевтические композиции
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
PH12017550077A1 (en) C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
UA120927C2 (uk) Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
BR112017009852A2 (pt) composto, composição, e, usos de um composto
BR112017009853A2 (pt) composto, composição, uso de uma quantidade melhoradora de hiv de um composto
TH147832A (th) ไทรเทอร์พีนอยด์ที่ถูกดัดแปลงที่ c-17 และ c-3 ที่มีฤทธิ์ยับยั้งการเจริญเติบโตของ hiv